Moors & Cabot’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.6M | Sell |
18,681
-1,726
| -8% | -$242K | 0.11% | 171 |
|
|
2025
Q4 | $2.5M | Buy |
20,407
+946
| +5% | +$115K | 0.11% | 180 |
|
|
2025
Q3 | $2.16M | Sell |
19,461
-1,992
| -9% | -$226K | 0.09% | 194 |
|
|
2025
Q2 | $2.38M | Sell |
21,453
-1,346
| -6% | -$143K | 0.11% | 175 |
|
|
2025
Q1 | $2.55M | Sell |
22,799
-274
| -1% | -$28.3K | 0.13% | 151 |
|
|
2024
Q4 | $2.13M | Sell |
23,073
-80
| -0.3% | -$7.2K | 0.1% | 170 |
|
|
2024
Q3 | $1.94M | Sell |
23,153
-192
| -0.8% | -$14.7K | 0.1% | 193 |
|
|
2024
Q2 | $1.6M | Sell |
23,345
-1,454
| -6% | -$97K | 0.09% | 213 |
|
|
2024
Q1 | $1.82M | Buy |
24,799
+3,220
| +15% | +$248K | 0.1% | 195 |
|
|
2023
Q4 | $1.75M | Sell |
21,579
-235
| -1% | -$18.3K | 0.11% | 179 |
|
|
2023
Q3 | $1.63M | Sell |
21,814
-1,482
| -6% | -$114K | 0.11% | 180 |
|
|
2023
Q2 | $1.8M | Sell |
23,296
-701
| -3% | -$55.9K | 0.12% | 170 |
|
|
2023
Q1 | $1.99M | Sell |
23,997
-3,294
| -12% | -$273K | 0.14% | 166 |
|
|
2022
Q4 | $2.34M | Sell |
27,291
-8,622
| -24% | -$683K | 0.16% | 141 |
|
|
2022
Q3 | $2.21M | Buy |
35,913
+2,558
| +8% | +$161K | 0.17% | 131 |
|
|
2022
Q2 | $2.06M | Buy |
33,355
+123
| +0.4% | +$7.62K | 0.15% | 151 |
|
|
2022
Q1 | $1.98M | Buy |
33,232
+3,408
| +11% | +$218K | 0.12% | 173 |
|
|
2021
Q4 | $2.17M | Sell |
29,824
-2,540
| -8% | -$175K | 0.13% | 159 |
|
|
2021
Q3 | $2.26M | Buy |
32,364
+660
| +2% | +$46.4K | 0.14% | 147 |
|
|
2021
Q2 | $2.18M | Buy |
31,704
+1,360
| +4% | +$90.8K | 0.15% | 143 |
|
|
2021
Q1 | $1.96M | Sell |
30,344
-96
| -0.3% | -$6.19K | 0.15% | 146 |
|
|
2020
Q4 | $1.77M | Sell |
30,440
-1,685
| -5% | -$102K | 0.15% | 149 |
|
|
2020
Q3 | $2.03M | Buy |
32,125
+1,918
| +6% | +$133K | 0.19% | 116 |
|
|
2020
Q2 | $2.33M | Buy |
30,207
+6,551
| +28% | +$502K | 0.25% | 93 |
|
|
2020
Q1 | $1.76M | Buy |
23,656
+800
| +4% | +$55.3K | 0.26% | 94 |
|
|
2019
Q4 | $1.48M | Sell |
22,856
-2,542
| -10% | -$166K | 0.15% | 148 |
|
|
2019
Q3 | $1.61M | Buy |
25,398
+4,167
| +20% | +$272K | 0.18% | 137 |
|
|
2019
Q2 | $1.44M | Buy |
21,231
+6,630
| +45% | +$436K | 0.18% | 133 |
|
|
2019
Q1 | $954K | Buy |
14,601
+321
| +2% | +$21.3K | 0.13% | 170 |
|
|
2018
Q4 | $894K | Sell |
14,280
-1,273
| -8% | -$89K | 0.14% | 161 |
|
|
2018
Q3 | $1.2M | Sell |
15,553
-1,254
| -7% | -$94.7K | 0.15% | 151 |
|
|
2018
Q2 | $1.19M | Sell |
16,807
-6,051
| -26% | -$427K | 0.16% | 152 |
|
|
2018
Q1 | $1.72M | Sell |
22,858
-1,107
| -5% | -$88K | 0.23% | 116 |
|
|
2017
Q4 | $1.71M | Sell |
23,965
-3,514
| -13% | -$267K | 0.23% | 116 |
|
|
2017
Q3 | $2.21M | Buy |
27,479
+2,496
| +10% | +$191K | 0.32% | 88 |
|
|
2017
Q2 | $1.77M | Sell |
24,983
-600
| -2% | -$39.9K | 0.29% | 96 |
|
|
2017
Q1 | $1.74M | Buy |
25,583
+1,832
| +8% | +$129K | 0.29% | 96 |
|
|
2016
Q4 | $1.7M | Sell |
23,751
-3,525
| -13% | -$262K | 0.28% | 99 |
|
|
2016
Q3 | $2.17M | Buy |
27,276
+4,782
| +21% | +$388K | 0.36% | 71 |
|
|
2016
Q2 | $1.87M | Sell |
22,494
-8,413
| -27% | -$747K | 0.33% | 75 |
|
|
2016
Q1 | $2.83M | Buy |
30,907
+6,994
| +29% | +$631K | 0.51% | 46 |
|
|
2015
Q4 | $2.41M | Sell |
23,913
-2,551
| -10% | -$265K | 0.44% | 62 |
|
|
2015
Q3 | $2.61M | Sell |
26,464
-1,249
| -5% | -$139K | 0.48% | 50 |
|
|
2015
Q2 | $3.25M | Buy |
27,713
+211
| +0.8% | +$23.1K | 0.53% | 45 |
|
|
2015
Q1 | $2.71M | Buy |
27,502
+3,625
| +15% | +$368K | 0.45% | 55 |
|
|
2014
Q4 | $2.24M | Buy |
23,877
+2,180
| +10% | +$225K | 0.38% | 67 |
|
|
2014
Q3 | $2.32M | Buy |
21,697
+5,990
| +38% | +$587K | 0.39% | 66 |
|
|
2014
Q2 | $1.3M | Buy |
15,707
+2,270
| +17% | +$177K | 0.22% | 113 |
|
|
2014
Q1 | $952K | Buy |
+13,437
| New | +$1.05M | 0.24% | 111 |
|
Other funds holding GILD
VCM
VPM
Moors & Cabot's GILD Position: Q1 2026 in Review
Moors & Cabot reduced its Gilead Sciences (GILD) stake by 8.5% in Q1 2026, selling an estimated $242K and leaving 18,681 shares worth $2.6M. The position accounts for 0.11% of the portfolio, ranked #171.
Moors & Cabot first reported a position in GILD in Q1 2014 and has held it in 49 quarters since. The position peaked at $3.25M in Q2 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Moors & Cabot held 18,681 shares of Gilead Sciences worth $2.6M as of Q1 2026.
- Moors & Cabot sold 1,726 Gilead Sciences shares in Q1 2026, an estimated $242K.
- Gilead Sciences made up 0.11% of Moors & Cabot's portfolio in Q1 2026, its #171 holding.
- Moors & Cabot first reported a position in Gilead Sciences in Q1 2014 and has held it in 49 quarters since.
- Moors & Cabot's Gilead Sciences position peaked at $3.25M in Q2 2015.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.